References
- Smith CI, Islam TC, Mattsson PT, et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays. 2001;23:436–446.
- Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152:557–565.
- Maas A, Hendriks RW. Role of Bruton’s tyrosine kinase in B cell development. Dev Immunol. 2001;8:171–181.
- Aadam Z, Kechout N, Barakat A, et al. X-linked agammagobulinemia in a large series of north African patients: frequency, clinical features and novel BTK mutations. J Clin Immunol. 2016;36:187–194.
- Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–728.
- Vetrie D, Vorechovský I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the Src family of protein-tyrosine kinases. Nature. 1993;361:226–233.
- Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–290.
- Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012;119:3744–3756.
- Whyburn LR, Halcomb KE, Contreras CM, et al. Reduced dosage of Bruton’s tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice. J Immunol. 2003;171:1850–1858.
- Nyhoff LE, Barron BL, Johnson EM, et al. Bruton’s tyrosine kinase deficiency inhibits autoimmune arthritis in mice but fails to block immune complex-mediated inflammatory arthritis. Arthritis Rheumatol. 2016;68:1856–1868.
- Uckun FM. Bruton’s tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol. 1998;56:683–691.
- Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–232.
- FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma. [cited 2017 Apr 18]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432123.htm
- European Medicines Agency. EPAR summary for the public. Imbruvica. Ibrutinib. [cited 2017 Apr 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003791/WC500177778.pdf
- Efficacy and safety study of CC-292 versus placebo as co-therapy with methotrexate in active rheumatoid arthritis. [cited 2017 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT01975610?term=btk+inhibitors&rank=102
- MSC2364447C Phase 1b in systemic lupus erythematosus. [cited 2017 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02537028?term=btk+inhibitors&rank=54
- A study of bendamustine and rituximab alone versus in combination with acalabrutinib in subjects with previously untreated mantle cell lymphoma. [cited 2017 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02972840?term=acp-196&rank=25
- Safety, tolerability and PK of BTK inhibitor DTRMWXHS-12 in patients with B-Cell lymphomas. [cited 2017 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02891590?term=btk+inhibitors&rank=2
- BTK inhibitor in B cell malignancies. [cited 2017 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02825836?term=btk+inhibitors&rank=8
- Musumeci F, Sanna M, Grossi G, et al. Pyrrolo[2,3-d]pyrimidines as kinase inhibitors. Curr Med Chem. 2017;24:1–27.
- Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton’s tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem. 1999;274:10983–10989.
- Vihinen M, Nilsson L, Smith CI. Tec homology (TH) adjacent to the PH domain. FEBS Lett. 1994;350:263–265.
- Park H, Wahl MI, Afar DE, et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 1996;4:515–525.
- Hashimoto S, Iwamatsu A, Ishiai M, et al. Identification of the SH2 domain binding protein of Bruton’s tyrosine kinase as BLNK-functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling. Blood. 1999;94:2357–2364.
- Ohya K, Kajigaya S, Kitanaka A, et al. Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. Proc Natl Acad Sci U S A. 1999;96:11976–11981.
- Dezorella N, Katz BZ, Shapiro M, et al. SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course. Haematologica. 2016;101:1553–1562.
- Mao C, Zhou M, Uckun FM. Crystal structure of Bruton’s tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem. 2001;276:41435–41443.
- Takata M, Kurosaki T. A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J Exp Med. 1996;184:31–40.
- De Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93–104.
- Jefferies CA, Doyle S, Brunner C, et al. Bruton’s tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem. 2003;278:26258–26264.
- Saito K, Scharenberg AM, Kinet JP. Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. J Biol Chem. 2001;276:16201–16206.
- Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene. 2000;19:5651–5661.
- Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science. 1996;271:822–825.
- Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58–73.
- Jr RR. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26–48.
- Xing L, Huang A. Bruton’s TK inhibitors: structural insights and evolution of clinical candidates. Future Med Chem. 2014;6:675–695.
- Kuglstatter A, Wong A, Tsing S, et al. Insights into the conformational flexibility of Bruton’s tyrosine kinase from multiple ligand complex structures. Protein Sci. 2011;20:428–436.
- Marcotte DJ, Liu YT, Arduini RM, et al. Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci. 2010;19:429–439.
- Li T, Tsukada S, Satterthwaite A, et al. Activation of Bruton’s tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity. 1995;2:451–460.
- Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–6296.
- Department of health and human services. Accelerated approval of Imbruvica. [cited 2017 Apr 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205552Orig1s016ltr.pdf
- European Medicines Agency. Public summary of opinion on orphan designation. Ibrutinib for the treatment of marginal zone lymphoma. [cited 2017 Apr 28]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/10/WC500194588.pdf
- Cilinicaltrials.gov 211 studies found for: ibrutinib. [cited 2017 Apr 28]. Available from: https://clinicaltrials.gov/ct2/results?term=ibrutinib&Search=Search
- Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem. 2007;2:58–61.
- Bender AT, Gardberg A, Pereira A, et al. Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-Cell receptor signaling. Mol Pharmacol. 2017;91:208–219.
- Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–2294.
- Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–87.
- Xu L, Tsakmaklis N, Yang G, et al. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017;129:2519–2525.
- Sharma S, Galanina N, Guo A, et al. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016;7:68833–68841.
- Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 2017;96:1175–1184.
- Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.
- Yasuhiro T, Yoshizawa T, Daub H, et al. ONO-WG-307, a novel, potent and selective inhibitor of Bruton’s tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. Cancer Res. 2012;72:2021.
- Phase I Study of ONO-4059 (ONO/GS-4059) given as monotherapy in patients with relapsed/refractory NHL and CLL. [cited 2017 Apr 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT01659255?term=ono-4059&rank=1
- Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127:411–419.
- Safety, PK/PD, food effect study of orally administered HM71224 in healthy adult male volunteers. [cited 2017 Apr 28]. Available from: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=o&submit_fld_opt=on&term=hm71224&show_flds=Y
- Park JK, Byun JY, Park JA, et al. HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther. 2016;18:91.
- Acerta Pharma B.V. Therapeutic combinations of a Mek inhibitor and a Btk inhibitor. WO2017033113. 2015.
- Covey T, Barf T, Gulrajani M, et al. ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia. Cancer Res. 2015;75(15 Suppl):Abstractnr 2596.
- Harrington BK, Gulrajani M, Covey T, et al. ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity. Blood. 2015;126:2908.
- Clinicaltrials.gov 26 studies found for: ACP-196. [cited 2017 Apr 28]. Available from: https://clinicaltrials.gov/ct2/results?term=acp-196&pg=1
- Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–332.
- Elevate CLL R/R: study of Acalabrutinib (ACP-196) versus ibrutinib in previously treated subjects with high risk chronic lymphocytic leukemia. [cited 2017 Apr 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02477696?term=NCT02477696&rank=1
- Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof. WO2009158571. 2009.
- Evans EK, Tester R, Aslanian S, et al. Clinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies. Blood. 2011;18:3485.
- Evans EK, Tester R, Aslanian S, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013;346:219–228.
- Clinicaltrials.gov 6 studies found for: CC-292. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&submit_fld_opt=on&term=CC-292&show_flds=Y
- Clinicaltrials.gov 4 studies found for: M2951. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/results?term=m2951&Search=Search
- Clinicaltrials.gov 1 study found for: M7583. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=n&submit_fld_opt=on&term=m7583&show_flds=Y
- Bender AT, Pereira A, Fu K, et al. Btk inhibition treats TLR7/IFN driven murine lupus. Clin Immunol. 2016;164:65–77.
- Li N, Sun Z, Liu Y, et al. BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia. Cancer Res. 2015;75(15Suppl):Abstractnr 2597.
- Tam C, Grigg AP, Opat S, et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-inhuman trial. Blood. 2015;126:832.
- Clinicaltrials.gov 4 studies found for: BGB-3111. [cited 2017 Jan 20]. Available from: https://clinicaltrials.gov/ct2/results?term=BGB-3111+&Search=Search
- Liu L, Di Paolo J, Barbosa J, et al. Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011;338:154–163.
- Young WB, Barbosa J, Blomgren P, et al. Potent and selective Bruton’s tyrosine kinase inhibitors: discovery of GDC-0834. Bioorg Med Chem Lett. 2015;25:1333–1337.
- Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7:41–50.
- Shi Q, Tebben A, Dyckman AJ, et al. Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases. Bioorg Med Chem Lett. 2014;24:2206–2211.
- Liu L, Halladay JS, Shin Y, et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor. Drug Metab Dispos. 2011;39:1840–1849.
- Young WB, Barbosa J, Blomgren P, et al. Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: pyridazinone analogs with improved metabolic stability. Bioorg Med Chem Lett. 2016;26:575–579.
- Watterson SH, De Lucca GV, Shi Q, et al. Discovery of 6-fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers. J Med Chem. 2016;59:9173–9200.
- Lee SK, Xing J, Catlett IM, et al. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. Eur J Clin Pharmacol. 2017;73:689–698.
- Clinicaltrials.gov 7 studies found for: BMS-986142. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=k&flds=n&flds=o&submit_fld_opt=on&term=BMS-986142&show_flds=Y
- Clinicaltrials.gov 1 study found for: AC0058TA. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=n&flds=o&submit_fld_opt=on&term=AC0058TA&show_flds=Y
- Hill RJ, Smith P, Krishnarajah J, et al. Discovery of PRN1008, a novel, reversible covalent BTK inhibitor in clinical development for rheumatoid arthritis. Arthritis Rheumatol. 2015;67(suppl 10). Available from: http://acrabstracts.org/abstract/discovery-of-prn1008-a-novel-reversible-covalent-btk-inhibitor-in-clinical-development-for-rheumatoid-arthritis/
- A study of PRN1008 in adult patients with Pemphigus vulgaris. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02704429?term=PRN1008&rank=1
- A Phase 1, single-ascending-dose, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) study of BIIB068 in healthy participants. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02829541?term=biib068&rank=1
- Clinicaltrials.gov 2 studies found for: DTRMWXHS-12. [cited 2017 Apr 20]. Available from: https://clinicaltrials.gov/ct2/results?term=DTRMWXHS-12&Search=Search
- Study of safety,efficacy and pharmacokinetics of CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02981745?term=CT-1530&rank=1
- Minke EB, Kevin LO, Brian TH, et al. SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5–9; Boston. Mol Cancer Ther. 2015;14(12Suppl 2):Abstractnr C186.
- Safety, PK, PD, and antitumor activity of SNS-062 in B lymphoid cancers. [cited 2017 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03037645?term=4+SNS-062&rank=1
- Pharmacyclics Inc. Inhibitors of Bruton’s tyrosine kinase. WO2013010136. 2013.
- Pharmacyclics Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors. WO2013102059. 2013.
- Principia Biopharma Inc. Tyrosine kinase inhibitors. WO2012158764. 2012.
- Serafimova IM, Pufall MA, Krishnan S, et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat Chem Biol. 2012;8:471–476.
- Copeland RA. The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov. 2016;15:87–95.
- Bradshaw JM, McFarland JM, Paavilainen VO, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol. 2015;11:525–531.
- Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases. WO2013191965. 2013.
- Principia Biopharma Inc. Treatment of dry eye. WO2014022569. 2014.
- Advinus Therapeutics Ltd. Bicyclic compounds, compositions and medicinal applications thereof. WO2013157021. 2013.
- Advinus Therapeutics Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof. WO2013157022. 2013.
- Thakkar M, Bhuniya D, Kaduskar R, et al. Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2017;27:1867–1873.
- Advinus Therapeutics Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof. US2015064196. 2015.
- Advinus Therapeutics Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof. EP3042903. 2016.
- Acea Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases. WO2014025486. 2014.
- Acea Biosciences Inc. Heterocyclic compounds and uses thereof. WO2015006754. 2015.
- Merck Sharp & Dohme. Btk inhibitors. WO2013010380. 2013.
- Taiho Pharmaceutical Co Ltd. Novel fused pyrimidine compound or salt thereof. WO2015022926. 2015.
- Pharmascience Inc. Protein kinase inhibitors. WO2015077866. 2015.
- Medivation Technologies Inc. Heterocyclic compounds and methods of use. WO2015058084. 2015.
- Hoffman-La Roche. Inhibitors of Bruton’s tyrosine kinase. WO2014064131. 2014.
- Novartis AG. Novel pyrrolo pyrimidine derivatives. WO2013008095. 2013.
- Biogen Idec Inc and Sunesis Pharmaceuticals Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology. WO2015089327. 2015.
- Redx Pharma Ltd. Compounds. GB2515785A. 2015.
- University of Utah Research Foundation. Substituted N-(3-(pyrimidin-4-yl) phenyl)acrylamide analogs as tyrosine receptor kinase Btk inhibitors. WO2014055928. 2014.
- Zhao X, Huang W, Wang Y, et al. Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold. Bioorg Med Chem. 2015;23:891–901.
- SciFinder - chemical abstract service. [ cited 2017 May 5]. Available from: http://scifinder.cas.org/
- Genentech Inc. Bicyclic piperazine compounds. WO2013067260. 2013.
- Johnson AR, Kohli PB, Katewa A, et al. Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations. ACS Chem Biol. 2016;11:2897–2907.
- Guo W, Liu R, Bhardwaj G, et al. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis. 2014;5:e1409.
- Wu H, Hu C, Wang A, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016;30:173–181.
- Baba Y, Hashimoto S, Matsushita M, et al. BLNK mediates SYK-dependent BTK activation. Proc Natl Acad Sci USA. 2001;98:2582–2586.
- Ma H, Qazi S, Ozer Z, et al. Regulatory phosphorylation of Ikaros by Bruton’s tyrosine kinase. PLoS One. 2013;8:e71302.
- Aw A, Brown JR. Current status of Bruton’s tyrosine kinase inhibitor development and use in B-cell malignancies. Drugs Aging. 2017 May 23;34:509–527. DOI:10.1007/s40266-017-0468-4